Lipopolysaccharide sensitizes neonatal hypoxic-ischemic brain injury in a MyD88-dependent manner

J Immunol. 2009 Dec 1;183(11):7471-7. doi: 10.4049/jimmunol.0900762. Epub 2009 Nov 16.

Abstract

Neurological deficits in children, including cerebral palsy, are associated with prior infection during the perinatal period. Experimentally, we have shown that pre-exposure to the Gram-negative component LPS potentiates hypoxic-ischemic (HI) brain injury in newborn animals. LPS effects are mediated by binding to TLR4, which requires recruitment of the MyD88 adaptor protein or Toll/IL-1R domain-containing adapter inducing IFN-beta for signal transduction. In this study, we investigated the role of MyD88 in neonatal brain injury. MyD88 knockout (MyD88 KO) and wild-type mice were subjected to left carotid artery ligation and 10% O(2) for 50 min on postnatal day 9. LPS or saline were administered i.p. at 14 h before HI. At 5 days after HI in wild-type mice, LPS in combination with HI caused a significant increase in gray and white matter tissue loss compared with the saline-HI group. By contrast, in the MyD88 KO mice there was no potentiation of brain injury with LPS-HI. MyD88 KO mice exhibited reduced NFkappaB activation and proinflammatory cytokine-chemokine expression in response to LPS. The number of microglia and caspase-3 activation was increased in the brain of MyD88 KO mice after LPS exposure. Collectively, these findings indicate that MyD88 plays an essential role in LPS-sensitized HI neonatal brain injury, which involves both inflammatory and caspase-dependent pathways.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Blotting, Western
  • Caspase 3 / drug effects
  • Caspase 3 / immunology
  • Caspase 3 / metabolism
  • Chemokines / biosynthesis
  • Enzyme Activation / drug effects
  • Enzyme Activation / immunology
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fluorescent Antibody Technique
  • Hypoxia-Ischemia, Brain / immunology*
  • Hypoxia-Ischemia, Brain / pathology*
  • Immunohistochemistry
  • Lipopolysaccharides / adverse effects*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Microglia / drug effects
  • Microglia / immunology
  • Myeloid Differentiation Factor 88 / immunology*
  • Myeloid Differentiation Factor 88 / metabolism
  • NF-kappa B / drug effects
  • NF-kappa B / immunology
  • NF-kappa B / metabolism
  • Polymerase Chain Reaction

Substances

  • Chemokines
  • Lipopolysaccharides
  • Myd88 protein, mouse
  • Myeloid Differentiation Factor 88
  • NF-kappa B
  • Caspase 3